New Zealand funds new methylphenidate ADHD treatment
This article was originally published in Scrip
Executive Summary
A new once daily treatment for attention deficit hyperactivity disorder (ADHD) has been funded by New Zealand's pharmaceutical management agencyPHARMAC.